List view / Grid view
The Phase III trials saw 75 percent of women in the relugolix combination therapy group achieve a reduction in dysmenorrhea (menstrual pain), compared with 30 percent or less of women in the placebo groups.
A Phase III study of oral relugolix has met its primary efficacy endpoint in men with advanced prostate cancer, supporting a New Drug Application submission to the FDA.
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
